Myriad Genetics (STU:MYD) E10: €-1.08 (As of Mar. 2026)


STU:MYD Myriad Genetics Inc STU:MYD
53 GF Score
Price €5.01
GF Value €12.90
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myriad Genetics E10?

Myriad Genetics STU:MYD +5.96% 53 E10 is €-1.08 as of Mar. 2026. GuruFocus rates STU:MYD with a GF Score™ of 53/100 and a GF Value™ of €12.90 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Myriad Genetics's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.311. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.08 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Myriad Genetics was 150.90% per year. The lowest was -32.00% per year. And the median was 15.30% per year.

As of today (2026-06-28), Myriad Genetics's current stock price is €5.012. Myriad Genetics's E10 for the quarter that ended in Mar. 2026 was €-1.08. Myriad Genetics's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Myriad Genetics was 178.31. The lowest was 9.46. And the median was 23.36.


Myriad Genetics  (STU:MYD) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Myriad Genetics was 178.31. The lowest was 9.46. And the median was 23.36.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Myriad Genetics E10 Related Terms


Myriad Genetics E10 Historical Data

* Premium members only.

The historical data trend for Myriad Genetics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myriad Genetics E10 Chart

Myriad Genetics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.65 0.42 -0.15 -0.46 -0.97

Myriad Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.81 -0.89 -0.97 -1.08

STU:MYD vs PRE, FLGT, IMDX: E10 Comparison

For the Diagnostics & Research subindustry, Myriad Genetics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics Shiller PE Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Shiller PE Ratio falls into.


STU:MYD
53GF Score
Myriad Genetics Inc STU:MYD
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Myriad Genetics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Myriad Genetics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.311/330.2130*330.2130
=-0.311

Current CPI (Mar. 2026) = 330.2130.

Myriad Genetics Quarterly Data

per share eps CPI Adj_EPS
201606 0.285 241.018 0.390
201609 -0.018 241.428 -0.025
201612 0.085 241.432 0.116
201703 0.056 243.801 0.076
201706 0.169 244.955 0.228
201709 0.940 246.819 1.258
201712 0.363 246.524 0.486
201803 0.105 249.554 0.139
201806 0.154 251.989 0.202
201809 -0.009 252.439 -0.012
201812 0.026 251.233 0.034
201903 0.080 254.202 0.104
201906 -0.053 256.143 -0.068
201909 -0.254 256.759 -0.327
201912 -0.099 256.974 -0.127
202003 -1.403 258.115 -1.795
202006 -0.657 257.797 -0.842
202009 -0.170 260.280 -0.216
202012 -0.419 260.474 -0.531
202103 -0.437 264.877 -0.545
202106 -0.050 271.696 -0.061
202109 0.255 274.310 0.307
202112 -0.089 278.802 -0.105
202203 -0.236 287.504 -0.271
202206 -0.170 296.311 -0.189
202209 -0.434 296.808 -0.483
202212 -0.491 296.797 -0.546
202303 -0.626 301.836 -0.685
202306 -1.311 305.109 -1.419
202309 -0.703 307.789 -0.754
202312 -0.330 306.746 -0.355
202403 -0.267 312.332 -0.282
202406 -0.381 314.175 -0.400
202409 -0.216 315.301 -0.226
202412 -0.449 315.605 -0.470
202503 0.000 319.799 0.000
202506 -3.095 322.561 -3.168
202509 -0.247 324.800 -0.251
202512 -0.068 324.054 -0.069
202603 -0.311 330.213 -0.311

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1.08 mean?
Myriad Genetics (STU:MYD) has a E10 of €-1.08 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Myriad Genetics and its competitors.
Is Myriad Genetics' E10 too high?
Myriad Genetics' current E10 is €-1.08. Overall, Myriad Genetics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' E10 compare to PRE and FLGT?
Myriad Genetics' E10 of €-1.08 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Medical Diagnostics & Research company?
A good E10 depends on the Medical Diagnostics & Research industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current E10 is €-1.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €12.90, compared to a current price of €5.01 — trading 61.1% below its estimated fair value. The current E10 is €-1.08. Myriad Genetics' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current E10 is €-1.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myriad Genetics (STU:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €5.01 is trading 61.1% below its estimated GF Value™ of €12.90. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for STU:MYD:

  • E10: €-1.08
  • GF Value™: €12.90 vs. price of €5.01 (61.1% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Myriad Genetics Business Description

Other Exchanges MYGN:USA0K3W:UKMYD:Germany
Address 322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
53GF Score

Get the complete analysis for STU:MYD

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.01
Price
€12.90
GF Value